<DOC>
	<DOCNO>NCT00087009</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Beta-glucan may increase effectiveness rituximab make cancer cell sensitive monoclonal antibody . PURPOSE : This phase I trial study side effect best dose beta-glucan give together rituximab treat young patient relapse progressive lymphoma leukemia lymphoproliferative disorder relate donor stem cell transplantation .</brief_summary>
	<brief_title>Beta-Glucan Rituximab Treating Young Patients With Relapsed Progressive Lymphoma Leukemia , Lymphoproliferative Disorder Related Donor Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose beta-glucan give combination rituximab pediatric patient relapse progressive CD20-positive lymphoma leukemia post-allogeneic stem cell transplant-related lymphoproliferative disorder . - Determine toxicity regimen , special emphasis degree B-cell depletion immune suppression , patient . - Determine effect beta-glucan leukocyte-mediated cytotoxic effect patient treat regimen . Secondary - Determine antitumor effect regimen patient . OUTLINE : This dose-escalation study beta-glucan . Patients assign 1 2 treatment group accord diagnosis . - Group I ( lymphoma leukemia ) : Patients receive rituximab IV day 1 , 8 , 15 , 22 oral beta-glucan daily day 1-28 ( day 8-28 course 1 ) . Treatment repeat every 42 day 4 course absence disease progression unacceptable toxicity . - Group II ( post-allogeneic stem cell transplant-related lymphoproliferative disorder ) : Patients receive rituximab IV day 1 , 4 , 8 , 15 , 22 oral beta-glucan daily day 8-28 . Beginning day 42 , patient respond disease may receive monthly rituximab prophylaxis CD4 cell count &gt; 200/mm^3 . Cohorts 6 patient receive escalate dos beta-glucan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 2 year . PROJECTED ACCRUAL : A total 6-24 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Bcell nonHodgkin 's lymphoma ( NHL ) Hodgkin 's lymphoma Posttransplant lymphoproliferative disorder ( PTLD ) Lymphoblastic leukemia CD20positive disease verify immunophenotyping original diagnosis , disease relapse , disease progression Refractory conventional therapy , define 1 following : Medically refractory HIVassociated NHL Refractory recurrent lymphoblastic leukemia PTLD In &gt; first relapse progression Bcell NHL Hodgkin 's lymphoma Measurable ( CT scan MRI ) evaluable ( marrow metastasis circulate lymphoblast ) disease within 4 week completion prior systemic ( include systemic steroid ) therapy PATIENT CHARACTERISTICS : Age Under 22 Performance status Not specify Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 500/mm^3* Platelet count &gt; 10,000/mm^3* NOTE : *Excluding patient PTLD CD20positive lymphoblastic leukemia Hepatic Hepatic toxicity ≤ grade 2 Renal Creatinine clearance ≥ 60 mL/min Renal toxicity ≤ grade 2 Cardiovascular Cardiac toxicity ≤ grade 2 Pulmonary Pulmonary toxicity ≤ grade 2 Immunologic Human antimouse antibody ( HAMA ) ≤ 1,000 units/mL Human antichimeric antibody titer negative No active , lifethreatening infection except EpsteinBarr virusassociated lymphoproliferative disorder No history allergy mouse proteins No history allergy rituximab chimeric monoclonal antibody No history allergy betaglucan oat , barley , mushroom , yeast Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Grade 3 hearing deficit allow Gastrointestinal toxicity ≤ grade 2 Neurologic toxicity ≤ grade 2 No severe major organ toxicity PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics More 4 week since prior rituximab No prior mouse antibody No prior chimeric antibody Chemotherapy Not specify Endocrine therapy See Disease Characteristics Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
</DOC>